Cartesian Therapeutics earnings were -$130.3M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest RNAC earnings report on Dec 31, 2025 announced Q4 2025 earnings of -$92.6M, up 157.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, RNAC reported annual earnings of -$130.3M, with 68.3% growth.
Cartesian Therapeutics Earnings Reports & History FAQ
What were Cartesian Therapeutics's earnings last quarter?
Cartesian Therapeutics (NASDAQ: RNAC) reported Q4 2025 earnings per share (EPS) of -$3.57, up 2,846.15% year over year. Total RNAC earnings for the quarter were -$92.58 million. In the same quarter last year, Cartesian Therapeutics's earnings per share (EPS) was $0.13.
Is Cartesian Therapeutics profitable or losing money?
As of the last Cartesian Therapeutics earnings report, Cartesian Therapeutics is currently losing money. Cartesian Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$130.30 million, a 68.3% increase year over year.
What was RNAC's earnings growth in the past year?
As of Cartesian Therapeutics's earnings date in Q1 2026, Cartesian Therapeutics's earnings has grown year over year. RNAC earnings in the past year totalled -$130.30 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.